NEW research presented at this year's European Congress on Obesity, held last week, shows that the obesity drug semaglutide is effective for weight loss in a multicentre, one-year-long real-world study.
A total of 305 patients were included in the analysis.
The percentage of patients that lost more than 5% of their body weight was 82%, more than 10% was 65%, more than 15% was 41%, and more than 20% was 21% at one year.
Semaglutide treatment also significantly decreased systolic and diastolic blood pressure by 6.8/2.5 mmHg; total cholesterol by 10.2 mg/dL; LDL by 5.1 mg/dL, and triglycerides by 17.6 mg/dL.
The authors concluded, "semaglutide was associated with significant weight loss and metabolic parameters improvement at one year in a multi-site real-world study".
The above article was sent to subscribers in Pharmacy Daily's issue from 23 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 May 23
